查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010047

癌症疫苗市场：2026-2032年全球市场预测（依产品类型、剂型、给药途径、研发阶段、适应症及最终用户划分）

Cancer Vaccines Market by Product Type, Formulations, Administration Pathway, Development Phase, Indication, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，癌症疫苗市场价值将达到 77.8 亿美元，到 2026 年将成长至 85.3 亿美元，到 2032 年将达到 150.8 亿美元，复合年增长率为 9.90%。

主要市场统计数据
基准年 2025 77.8亿美元
预计年份：2026年 85.3亿美元
预测年份 2032 150.8亿美元
复合年增长率 (%) 9.90%

简要概述正在重塑癌症疫苗研发和相关人员决策的科学、临床和商业性因素的融合。

癌症疫苗领域正处于关键的转折点，这得益于数十年的免疫学研究、分子生物学的进步以及基于免疫的肿瘤解决方案的商业性化復苏。本执行摘要整合了塑造该领域的核心趋势，概述了新型抗原发现、递送平台和转化科学如何融合，从而重新定义恶性肿瘤的治疗和预防方法。透过重点介绍创新驱动因素、不断变化的监管以及临床应用中的瓶颈，本导言为后续的详细分析章节奠定了基础。

平台成熟度、与适应性强的监管机构的合作以及策略伙伴关係正在从根本上改变发展路径和竞争优势的动态。

过去几年，癌症疫苗领域经历了翻天覆地的变化，涵盖了从零星的科学突破到平台演进、监管调整以及产业策略重组等各个面向。首先，核酸平台的成熟加速了原型疫苗的研发，并简化了疫苗的迭代设计。因此，研发人员目前正致力于采用混合策略，将现成的组件与个人化的新抗原有效载荷相结合，从而改变了专案设计和临床开发的週期。

本研究评估了 2025 年关税变化和贸易政策转变将如何影响整个疫苗生态系统的采购、製造韧性和临床试验物流。

2025年关税的实施和贸易政策调整对支持癌症疫苗研发和商业化的全球供应链产生了复杂的影响。由于关税导致试剂、一次性塑胶和某些生物製程组件的投入成本增加，促使筹资策略改变，迫使赞助商重新评估供应商多元化和近岸外包方案。因此，各组织必须在成本控制和维持高品质、合规的供应链之间取得平衡，以确保其敏感的生技药品务顺利进行。

分析多方面的细分，并在涵盖适应症和医疗保健环境的差异化疫苗项目中，协调配方、临床策略和医疗保健服务。

细分市场层面的趋势揭示了不同的需求和机会，这有助于制定产品策略、临床设计和市场推广计划。根据产品类型，该领域可分为预防性癌症疫苗和治疗性癌症疫苗，二者针对不同的目标族群、监管管道和商业性价值提案。预防性疫苗需要广泛的安全性和长期监测系统，而治疗性疫苗则强调肿瘤特异性免疫抗原性和联合治疗以达到持续疗效。

全球范围内监管差异、临床能力和生产能力如何影响研发重点和打入市场策略？

区域趋势对整个癌症疫苗领域的研发重点、监管互动和商业化规划都产生显着影响。在美洲，活跃的创业投资活动、先进的临床试验基础设施和成熟的生物製造网路为快速迭代研发和早期人体试验提供了支援。因此，申办方通常会优先考虑在这些市场进行「首次人体试验」并积极与监管机构沟通，以降低科学风险并确保早期临床疗效。

对决定该领域竞争差异化和合作伙伴关係吸引力的策略经营模式、伙伴关係动态和营运能力进行评估。

癌症疫苗领域的企业策略呈现出多元化的模式，涵盖了从垂直整合的创新企业到专业技术提供者和生产合作伙伴等各个方面。生技公司致力于打造差异化平台，专注于发展其专有的抗原发现引擎；而大型製药企业则日益关注将疫苗整合到联合治疗中，以充分利用其现有的癌症治疗产品组合。在整个生态系统中，策略联盟、许可协议和共同开发契约是获取互补能力和缩短临床试验时间的关键机制。

生物製药公司领导者可以采取切实可行的、以里程碑为基础的步骤来降低专案风险、加速临床应用并增强与支付者和合作伙伴的议价能力。

领先机构需要采取实际有效的措施，将科学潜力转化为永续的临床和商业性成果。首先，应优先进行平台检验，透过精心设计的转化研究，将基于机制的生物标记与有意义的临床终点联繫起来。这种方法可以降低后期试验的退出率，并加强与监管机构和支付方的沟通。其次，应投资于灵活的生产结构和双源采购策略，以降低供应链风险，并快速应对专案迭代调整。

透明、多方面的研究途径结合了初步访谈、专家文献和分析检验，为切实可行的实证建议提供了支持。

本研究采用混合方法，整合了第一手访谈、严谨的二手资料研究和分析三角验证，以确保获得可靠且可操作的见解。第一手资料研究包括对行业高管、临床研究人员、生产专家和支付方顾问进行结构化访谈，以了解他们对营运限制、试验设计偏好和商业性准入预期等方面的真实观点。这些定性资料与公开的监管指南、同侪审查文献和企业资讯披露相结合，从而全面了解产业动态。

将科学机会与实施要求结合，明确领导者应如何平衡创新、韧性和策略伙伴关係以取得成功。

总之，癌症疫苗领域瞬息万变，科学创新、商业性机会和营运复杂性在此交汇融合。平台技术和转化科学的进步拓宽了可能性，但要实现临床和商业性的成功，需要在生产製造、监管策略和医保支付方参与等方面进行严谨的执行。此外，贸易政策和供应链考量如今已成为研发计画不可或缺的组成部分，我们鼓励申办方采用能够兼顾多元化采购和地理因素的生产策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 癌症疫苗市场：依产品类型划分

  • 预防性癌症疫苗
  • 用于治疗的癌症疫苗

第九章 癌症疫苗市场（依製剂类型划分）

  • 细胞疫苗
    • 树突细胞疫苗
    • 癌细胞疫苗
  • 核酸疫苗
    • DNA疫苗
    • RNA疫苗
  • 胜肽/蛋白质疫苗
  • 合成疫苗
  • 病毒载体疫苗

第十章：癌症疫苗市场依给药途径划分

  • 肌肉内部
  • 静脉

第十一章：癌症疫苗市场依研发阶段划分

  • 临床试验
  • 第一阶段
  • 第二阶段
  • 第三阶段

第十二章：癌症疫苗市场：依适应症划分

  • 乳癌
  • 结肠癌
  • 肺癌
  • 恶性黑色素瘤
  • 摄护腺癌

第十三章：癌症疫苗市场：依最终用户划分

  • 癌症研究机构
  • 医院和诊所
  • 癌症治疗中心

第十四章 癌症疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：癌症疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 癌症疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国癌症疫苗市场

第十八章：中国癌症疫苗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advaxis Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Bristol Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • CureVac SE
  • Dynavax Technologies Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GSK PLC
  • Helsinn Healthcare SA
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc
  • JW CreaGene
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sanpower Group Co., Ltd.
  • Scorpius Holdings, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Vaxine Pty Ltd
Product Code: MRR-434CCDA0514B

The Cancer Vaccines Market was valued at USD 7.78 billion in 2025 and is projected to grow to USD 8.53 billion in 2026, with a CAGR of 9.90%, reaching USD 15.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.78 billion
Estimated Year [2026] USD 8.53 billion
Forecast Year [2032] USD 15.08 billion
CAGR (%) 9.90%

A concise orientation to the scientific, clinical, and commercial forces converging to reshape cancer vaccine development and stakeholder decision-making

The field of cancer vaccines is at a pivotal inflection point driven by decades of immunology research, advances in molecular biology, and renewed commercial interest in immune-based oncology solutions. This executive summary synthesizes core dynamics shaping the sector, framing how novel antigen discovery, delivery platforms, and translational science converge to redefine therapeutic and preventive approaches to malignancies. By clarifying the drivers of innovation, regulatory evolution, and clinical translation bottlenecks, this introduction sets context for the deeper analytical sections that follow.

Importantly, the landscape combines established scientific principles with rapid technological iteration, meaning that incremental improvements in vaccine design can yield outsized clinical and operational benefits. As such, stakeholders must view scientific breakthroughs alongside commercialization realities including manufacturing complexity, supply chain resilience, and reimbursement environments. Moving forward, this report adopts an integrated lens that links scientific promise to practical execution, enabling decision-makers to prioritize investments that balance near-term clinical feasibility with longer-term strategic differentiation.

How platform maturation, adaptive regulatory engagement, and strategic alliances are fundamentally altering development pathways and competitive advantage dynamics

Over the past several years the cancer vaccine landscape has undergone transformative shifts that extend beyond isolated scientific breakthroughs to encompass platform evolution, regulatory recalibration, and strategic industry realignment. First, the maturation of nucleic acid platforms has accelerated iterative vaccine designs that are faster to prototype and easier to personalize. Consequently, developers now pursue hybrid strategies that combine off-the-shelf components with individualized neoantigen payloads, driving a shift in program design and clinical development timelines.

Concurrently, manufacturing innovations and the rise of experienced contract development and manufacturing organizations have altered capacity planning and lowered some barriers to scale. In parallel, regulators have signaled a willingness to engage early on platform-specific endpoints and adaptive trial designs, which has encouraged sponsors to pursue pragmatic pathways to demonstrate clinical benefit. At the same time, commercial strategies have shifted from single-product plays to ecosystem-focused approaches that pair vaccines with companion diagnostics, checkpoint inhibitors, or radiotherapy to enhance response durability.

These combined shifts mean that competitive advantage will increasingly accrue to organizations that can integrate rapid antigen discovery, flexible manufacturing, and robust translational biomarker programs. As a result, partnerships and strategic alliances are becoming a primary vehicle for accelerating development while distributing risk across specialized collaborators.

Assessing how tariff shifts and trade policy changes in 2025 are reshaping procurement, manufacturing resilience, and clinical trial logistics across the vaccine ecosystem

The imposition of tariffs and trade policy adjustments in 2025 introduced a complex overlay on the global supply chains that underpin cancer vaccine research, development, and commercialization. Tariff-driven increases in input costs for reagents, single-use plastics, and certain bioprocessing components have altered procurement strategies and prompted sponsors to re-evaluate supplier diversification and nearshoring options. In turn, organizations must reconcile the tension between cost management and the necessity of maintaining high-quality, compliant supply chains for sensitive biologics work.

Moreover, tariffs have affected cross-border movement of clinical trial materials and investigational products, adding administrative complexity and potential delays in multinational study execution. Consequently, trial sponsors are adjusting logistics planning, expanding buffer stocks, and engaging earlier with customs and regulatory stakeholders to minimize disruption. In addition, the cumulative policy environment has influenced investor sentiment and capital allocation decisions, particularly for early-stage companies that rely on international partnerships for manufacturing or distribution.

From a strategic standpoint, the most resilient organizations respond by mapping critical suppliers, identifying substitute inputs, and negotiating longer-term procurement agreements. At the same time, decision-makers are evaluating investments in regional manufacturing capacity and collaborative consortia that spread tariff exposure while preserving the agility required for iterative vaccine development.

Interpreting multi-dimensional segmentation to align formulation, clinical strategy, and care delivery for differentiated vaccine programs across indications and settings

Segment-level dynamics reveal differentiated needs and opportunities that inform product strategy, clinical design, and go-to-market planning. Based on product type, the field separates into preventive cancer vaccines and therapeutic cancer vaccines, each with distinct target populations, regulatory pathways, and commercial value propositions. Preventive approaches necessitate broad safety and long-term surveillance frameworks, whereas therapeutic vaccines emphasize tumor-specific immunogenicity and combination regimens to achieve durable responses.

Based on formulations, developers are advancing multiple modalities including cell-based vaccines, nucleic acid-based vaccines, peptide and protein constructs, synthetic vaccines, and viral vector systems. Within cell-based approaches, dendritic cell vaccines and tumor cell vaccines offer different manufacturing complexity and personalization trade-offs. Similarly, nucleic acid-based platforms differentiate into DNA vaccines and RNA vaccines, with each presenting unique delivery and stability considerations that affect clinical deployment.

Based on administration pathway, studies and clinical operations focus on intramuscular and intravenous delivery routes, choices that influence patient experience, pharmacokinetics, and site-of-care logistics. Based on development phase, programs span clinical trials across Phase I, Phase II, and Phase III, shaping evidence requirements and regulatory engagement strategies. Based on indication, teams prioritize target malignancies such as breast cancer, colorectal cancer, lung cancer, melanoma, and prostate cancer, each of which imposes distinct biomarker, endpoint, and competitive considerations. Based on end-user, adoption pathways vary across cancer research institutes, hospitals and clinics, and specialty cancer treatment centers, factors that inform commercialization and reimbursement planning.

Taken together, these segmentation lenses illustrate that no single development path fits all programs; instead, sponsors must align formulation, delivery, and clinical strategy to the indication, patient population, and intended care setting to optimize chances of successful translation.

How regional regulatory nuance, clinical capacity, and manufacturing capabilities across global regions shape development priorities and market entry strategies

Regional dynamics significantly influence development priorities, regulatory engagement, and commercial planning across the cancer vaccine landscape. In the Americas, strong venture capital activity, advanced clinical trial infrastructure, and established biomanufacturing networks support rapid iteration and early human testing. Consequently, sponsors often prioritize first-in-human studies and regulatory interactions in these markets to de-risk science and secure early clinical validation.

In Europe, Middle East & Africa, diverse regulatory frameworks and varying reimbursement pathways require tailored evidence generation strategies, while the region's strong academic networks and collaborative research consortia provide fertile ground for translational science and investigator-initiated trials. Stakeholders operating in this region often engage early with regional regulators and payers to harmonize clinical endpoints and access pathways.

In the Asia-Pacific region, accelerating public and private investment in biotechnology, expanding manufacturing capacity, and growing patient populations create opportunities for large-scale studies and regional manufacturing partnerships. However, developers must navigate heterogeneous regulatory timelines and local clinical practice patterns. Across all regions, successful strategies combine global program design with regional execution plans that account for regulatory nuance, supply chain considerations, and local stakeholder engagement to enable efficient development and market entry.

Evaluating strategic business models, partnership dynamics, and operational capabilities that determine competitive differentiation and partnership appeal in the sector

Company strategies in the cancer vaccine sector reflect a spectrum of models that range from vertically integrated innovators to specialized technology providers and manufacturing partners. Biotech companies pursue differentiated platforms with an emphasis on proprietary antigen discovery engines, while larger pharmaceutical firms are increasingly focused on integrating vaccines into combination regimens that leverage their existing oncology portfolios. Across the ecosystem, strategic collaborations, licensing agreements, and co-development arrangements serve as primary mechanisms to obtain complementary capabilities and accelerate time to clinic.

Notably, contract development and manufacturing organizations play a pivotal role by enabling smaller developers to access GMP-compliant production and scale-up expertise without the capital intensity of building internal capacity. In addition, diagnostic developers and biomarker companies are becoming essential allies, providing the companion tools needed to select patients and measure pharmacodynamic responses. Investors and corporate development teams are therefore evaluating partner fit across technical proficiency, regulatory experience, and cultural alignment to manage program risk.

Ultimately, competitive differentiation will depend on the ability to combine scientific novelty with operational excellence, regulatory foresight, and reimbursement strategy. Companies that can demonstrate reproducible manufacturing, robust translational datasets, and clear paths to payer evidence will command strategic advantage in partnerships and capital markets.

Practical, milestone-driven steps that biopharma leaders can implement to de-risk programs, accelerate clinical translation, and strengthen payer and partner negotiations

Leading organizations must adopt pragmatic, high-impact actions to translate scientific potential into durable clinical and commercial outcomes. First, prioritize platform validation through well-designed translational studies that link mechanistic biomarkers to meaningful clinical endpoints; this approach reduces late-stage attrition and strengthens conversations with regulators and payers. Next, invest in flexible manufacturing arrangements and dual-sourcing strategies to mitigate supply chain risk and respond quickly to iterative program adjustments.

Additionally, pursue strategic collaborations that align scientific synergies with operational needs, such as partnering with diagnostic developers to co-develop companion assays or engaging experienced CDMOs to accelerate GMP manufacturing timelines. Further, adopt adaptive clinical trial designs and real-world evidence collection strategies to generate robust datasets that support both regulatory submissions and payer negotiations. From a commercial perspective, refine value propositions by mapping patient pathways and stakeholder economics to ensure pricing and access strategies reflect clinical differentiation and real-world impact.

Finally, build internal capabilities in regulatory strategy, health economics and outcomes research, and manufacturing science to reduce dependence on external partners and to retain negotiating leverage. By sequencing these actions and establishing clear milestone-based decision gates, leaders can preserve optionality while accelerating programs that demonstrate the highest probability of clinical and commercial success.

A transparent, multi-source research approach combining primary interviews, technical literature, and analytical validation to underpin practical, evidence-based recommendations

This research employs a mixed-methods approach that integrates primary interviews, rigorous secondary research, and analytical triangulation to ensure robust and actionable findings. Primary research included structured interviews with industry executives, clinical investigators, manufacturing experts, and payer advisors to capture real-world perspectives on operational constraints, trial design preferences, and commercial access expectations. These qualitative inputs were synthesized with publicly available regulatory guidance, peer-reviewed literature, and company disclosures to construct a comprehensive understanding of sector dynamics.

Secondary research encompassed literature review, analysis of clinical trial registries, and technical white papers that document platform performance, safety profiles, and biomarker strategies. The methodology also applied comparative analysis across regional regulatory frameworks and supply chain configurations to highlight executional risks and opportunities. Analytical validation steps included cross-checking interview insights against documented trial outcomes and manufacturing case studies, and conducting scenario analysis to explore policy and operational contingencies.

Limitations of the approach are acknowledged; for instance, proprietary internal data from private firms may not be fully accessible, and rapidly evolving trial outcomes can shift competitive positions. Nevertheless, the triangulated methodology provides a defensible basis for strategic recommendations and enables stakeholders to tailor the insights to their specific portfolio and risk appetite.

A synthesis of scientific opportunity and executional requirements that clarifies how leaders must balance innovation, resilience, and strategic partnerships to succeed

In conclusion, cancer vaccines occupy a dynamic intersection of scientific innovation, commercial opportunity, and operational complexity. Advances in platform technologies and translational science have expanded the realm of possibility, but realizing clinical and commercial impact requires disciplined execution across manufacturing, regulatory strategy, and payer engagement. Moreover, trade policy and supply chain considerations are now integral to development planning, motivating sponsors to adopt diversified sourcing and geographically informed manufacturing strategies.

Going forward, organizations that integrate rigorous biomarker-driven program designs with flexible manufacturing and strategic partnerships will be best positioned to navigate the competitive environment. Strategic patience, combined with targeted investments in clinical validation and operational resilience, will enable sponsors to convert scientific promise into patient benefit. Ultimately, the path to success is multifaceted and demands that scientific ambition be matched by pragmatic, well-resourced execution across the entire product lifecycle.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Vaccines Market, by Product Type

  • 8.1. Preventive Cancer Vaccines
  • 8.2. Therapeutic Cancer Vaccines

9. Cancer Vaccines Market, by Formulations

  • 9.1. Cell-Based Vaccines
    • 9.1.1. Dendritic Cell Vaccines
    • 9.1.2. Tumor Cell Vaccines
  • 9.2. Nucleic Acid-Based Vaccines
    • 9.2.1. DNA Vaccines
    • 9.2.2. RNA Vaccines
  • 9.3. Peptide/Protein-Based Vaccines
  • 9.4. Synthetic Vaccines
  • 9.5. Viral Vector-Based Vaccines

10. Cancer Vaccines Market, by Administration Pathway

  • 10.1. Intramuscular
  • 10.2. Intravenous

11. Cancer Vaccines Market, by Development Phase

  • 11.1. Clinical Trials
  • 11.2. Phase I
  • 11.3. Phase II
  • 11.4. Phase III

12. Cancer Vaccines Market, by Indication

  • 12.1. Breast Cancer
  • 12.2. Colorectal Cancer
  • 12.3. Lung Cancer
  • 12.4. Melanoma
  • 12.5. Prostate Cancer

13. Cancer Vaccines Market, by End-User

  • 13.1. Cancer Research Institutes
  • 13.2. Hospitals & Clinics
  • 13.3. Specialty Cancer Treatment Centers

14. Cancer Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cancer Vaccines Market

18. China Cancer Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Advaxis Inc.
  • 19.6. Amgen Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Bayer AG
  • 19.9. BioNTech SE
  • 19.10. Bristol Myers Squibb Company
  • 19.11. Celldex Therapeutics, Inc.
  • 19.12. CureVac SE
  • 19.13. Dynavax Technologies Corporation
  • 19.14. Eli Lilly and Company
  • 19.15. F. Hoffmann-La Roche AG
  • 19.16. GSK PLC
  • 19.17. Helsinn Healthcare SA
  • 19.18. Inovio Pharmaceuticals, Inc.
  • 19.19. Johnson & Johnson Services, Inc
  • 19.20. JW CreaGene
  • 19.21. Merck & Co., Inc.
  • 19.22. Moderna, Inc.
  • 19.23. Pfizer Inc.
  • 19.24. Sanofi SA
  • 19.25. Sanpower Group Co., Ltd.
  • 19.26. Scorpius Holdings, Inc.
  • 19.27. Serum Institute of India Pvt. Ltd.
  • 19.28. Sun Pharmaceutical Industries Ltd.
  • 19.29. Vaxine Pty Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CANCER VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. GCC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 171. GCC CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. G7 CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 198. G7 CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 199. G7 CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 200. G7 CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 201. G7 CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 204. NATO CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 207. NATO CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 208. NATO CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 209. NATO CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)